32 results
8-K
PNT
POINT Biopharma Global Inc.
13 Jun 23
Departure of Directors or Certain Officers
4:45pm
on the Company’s Nominating and Corporate Governance Committee.
Dr. Martell is a pharmaceutical executive. She started her pharmaceutical career at Pfizer
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
Inspections 100 Part III 101 Item 10. Directors, Executive Officers and Corporate Governance 101 Item 11. Executive Compensation 101 Item 12. Security …
PART III Item 10. Directors, Executive Officers and Corporate Governance Incorporated herein by reference to our definitive proxy statement for our
424B3
PNT
POINT Biopharma Global Inc.
11 Jul 22
Prospectus supplement
4:32pm
with the SEC on March 25, 2022, entitled “Item 10. Directors, Executive Officers and Corporate Governance,” “Item 11. Executive Compensation” and “Item 13
POS AM
PNT
POINT Biopharma Global Inc.
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
with the SEC on March 25, 2022, entitled “Item 10. Directors, Executive Officers and Corporate Governance,” “Item 11. Executive Compensation” and “Item 13
DEF 14A
ca9d 2b08xhi
28 Apr 22
Definitive proxy
8:36am
424B3
fol7mkgtc 3k3
31 Mar 22
Prospectus supplement
11:42am
POS AM
swm 531zoyk2
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
pq64q 72l3zv
5 Aug 21
Prospectus supplement
4:26pm
8-K
36lx5ub8ypax3py8h2
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
8-K
EX-3.2
idcde mce7bo
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
424B3
xsenoh3ylhysybnr8d
9 Jun 21
Prospectus supplement
4:42pm
S-4/A
p9y12oiou
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4
enjcxn
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
8-K/A
EX-2.1
rh512a203 6oop
18 Mar 21
Financial Statements and Exhibits
9:08am
10-K
dov z3jpz
5 Mar 21
Annual report
8:13am